Royalty Pharma plc — Director's Dealing 2025

May 14, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2025-05-12

Reporting Person: Legorreta Pablo G. (Director, CEO, Chairman of the Board)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-12	Class B Ordinary Shares	$0	G	867180	Disposed		Class A Ordinary Shares (867180)	Indirect
2025-05-12	Class B Ordinary Shares	$0	G	867180	Acquired		Class A Ordinary Shares (867180)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Class B Ordinary Shares	$0		Class A Ordinary Shares (9700000)	9700000	Indirect

Footnotes

F1: Reflects an exempt gift for no consideration of Class B ordinary shares ("Class B Shares") of Royalty Pharma Holdings Ltd ("RPH") from the reporting person's spouse to the reporting person. The Class B Shares held by the reporting person's spouse were originally received in an exempt pro rata distribution pursuant to Rule 16a-9(a).

F2: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

F3: Reflects the exempt transfer pursuant to Rule 16a-13 of Class B Shares from the reporting person and the GST-Exempt Legorreta 2020 Family Trust to PL RPH AIV, LLC, which is solely beneficially owned by the reporting person. The Class B Shares transferred by the reporting person and the GST-Exempt Legorreta 2020 Family Trust were originally received in exempt pro rata distributions pursuant to Rule 16a-9(a) and the gift transaction reported in this filing.